Revolution Medicines is trading at $180.77, down 10.01%, amid broad risk-off pressure; no clear company-specific catalyst was identified. - Reuters reported U.S. stocks edged lower as surging oil and near-multidecade-high Treasury yields intensified inflation concerns. - Biotech weakness adds context but does not establish a company-specific catalyst. The latest reported Phase 3 trial start predates October 8. - Live-session volume data was not provided.